05/10/23 5:51 AMNasdaq : SVA covid-19SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 VaccinesSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced it will provide its inactivated COVID-19 vaccine, CoronaVac ®, to self-paying groups in Hong Kong. Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect...RHEA-AIneutral
05/01/23 6:00 AMNasdaq : SVA earningsSINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-FSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20- F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022. The Company also reported its unaudited financial for the second half and audited financial for full year ended December 31, 2022..RHEA-AIneutral
02/22/23 6:00 AMNasdaq : SVA Sinovac Amends Shareholder Rights PlanSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. Sinovac Biotech Ltd. is a China- based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.RHEA-AIneutral
12/29/22 8:30 AMNasdaq : SVA earningsSINOVAC Reports Unaudited First Half of 2022 Financial ResultsSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2022. Sales for the six-month period ended June 30, 2022 were $1.2 billion, compared to $11.0 billion in the prior year period. Net income attributable to common shareholders totaled...RHEA-AIneutral
11/03/22 10:03 PMNasdaq : SVA SINOVAC Varicella Vaccine Prequalified by WHOSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.RHEA-AIneutral
10/28/22 5:00 AMNasdaq : SVA SINOVAC to Showcase Products at CPHI FrankfurtSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the world’ s largest pharmaceutical exhibitions, from 1 st to 3 rd of November, in Frankfurt, Germany. At Booth #41 G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present...RHEA-AIneutral
09/06/22 6:00 AMNasdaq : SVA clinical trialcovid-19SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in ChileSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine on August 31st. Weidong Yin, the Chairman, President, and CEO of SINOVAC said,“ SINOVAC has made great...RHEA-AIneutral
08/18/22 5:56 PMNasdaq : SVA Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sinovac To Contact Him Directly To Discuss Their OptionsFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against 1Globe Capital LLC ("1Globe") on behalf of a class consisting of all holders of Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA) stockRHEA-AInegative
08/03/22 6:00 AMNasdaq : SVA covid-19SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong KongSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’ s Republic of China has approved the Company’ s COVID-19 vaccine,...RHEA-AIneutral
07/19/22 1:30 AMNasdaq : SVA clinical trialSINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in ChileSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’ s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile. In total, there will be 1,600 volunteers recruited, half of...RHEA-AIneutral